Berenberg Bank analyst Gal Munda maintained a Buy rating on AbCellera Biologics (ABCL – Research Report) today and set a price target of $53.00. The company’s shares closed last Thursday at $41.56, close to its 52-week low of $36.27.
Munda has an average return of 13.9% when recommending AbCellera Biologics.
According to TipRanks.com, Munda is ranked #672 out of 7227 analysts.
AbCellera Biologics has an analyst consensus of Strong Buy, with a price target consensus of $51.40, which is a 15.8% upside from current levels. In a report issued on January 5, BMO Capital also initiated coverage with a Buy rating on the stock with a $48.00 price target.
Based on the recent corporate insider activity of 9 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ABCL in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
AbCellera Biologics Inc is a biotechnology company. The company develops antibodies to treat highly infectious diseases and various other types of diseases.